Topic:Vaccine development
Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
The immune response of horses to tetanus toxoid. An intramuscular injection of 8-16 Lf tetanus toxoid in water-in-oil emulsion protected adult horses against tetanus for at least 128 weeks. A booster dose of 8 Lf toxoid in aqueous solution protected them for a further period of at least 3 1/2 years. Colostral immunity protected foals for at least 10 weeks. An intramuscular injection of 8 Lf toxoid in water-in-oil emulsion given to foals from immune dams when they were 10-18 weeks old did not elicit any antibody response. They did respond, however, to a booster injection of 8 Lf toxoid in aqueous solution given 12 weeks after the first dose. ...
Studies on cross protection induced in calves by rotaviruses of calves, children and foals. Inoculation at birth with a live attenuated strain of a bovine rotavirus isolated in the USA (scourvax-reo) induced protection in five gnotobiotic calves seven to 21 days later against a UK isolate of pathogenic bovine rotavirus. However, no protection was induced in three calves challenged three to five days after vaccination. There was a close antigenic relationship demonstrated between the two bovine rotavirus isolates. In contrast only one of three gnotobiotic calves inoculated with foal rotavirus, and one of three with human rotavirus, were protected against bovine rotavirus challenge. Pr...
Homologous and cross-reactive precipitins in anti-pneumococcal sera raised in mules. Serial bleedings were obtained from two mules during prolonged immunization, one with type XXV the other with type VIII pneumococcal vaccine. IgGa, IgGb, IgGc, IgB, IgG(T) and IgM present among purified Pn anti-XXV and Pn anti-VIII immunoglobulin isolated from various bleedings were identified by use of rabbit anti-equine heavy chain specific reagents. Radioimmunodiffusion with 14C-labelled type XXV pneumococcal capsular polysaccharide and horse and donkey reagents with species specificity directed against donkey or horse IgGa respectively, demonstrated both parental horse and donkey IgGa heav...
Radioimmunoassay for quantitation of antibodies to alphaviruses with staphylococcal protein A. A radioimmunoassay (RIA) procedure is described for measuring antibodies to alphaviruses in human and other mammalian sera. The test employed protein Abearing Staphylococcus aureus as a solid-phase immunoadsorbent for (3)H-labeled viruses complexed with immunoglobulin G. Using antibodies produced in humans and guinea pigs, the RIA procedure clearly differentiated among antibodies to Venezuelan, western, and eastern equine encephalomyelitis viruses. Sensitivity of the RIA depended on the concentrations of labeled viruses employed. The dilution of serum that effected binding of 50% of the (3)H-l...
Equine rhinopneumonitis vaccine: immunogenicity and safety in foals. Immunogenicity and safety of an equine herpesvirus 1 (ehv-1) vaccine were studied in 111 foals varying in age from 1 to 122 days. Each of 88 principals was given 1 im injection of vaccine. Five of the 88 foals were revaccinated; 69 of the vaccinated principals and 23 nonvaccinated foals (serving as controls) were challenge exposed intranasally with virulent ehv-1.
The vaccine failed to cause adverse local or systemic reaction in 88 principals with serunirneutralization (sn) titers against ehv-1 varying between 0 to 1:256 at time of vaccination. After vaccination, the foals' body temperature...
Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses. Twenty-nine horses were vaccinated with a trivalent (Venezuelan, eastern, and western) inactivated equine encephalomyelitis virus vaccine. The vaccine purchased for this study was the only one licensed and commercially available in May, 1975. Plaque-neutralizing and hemagglutinin-inhibiting antibodies in response to each of the 3 equine encephalomyelitis viruses were determined after vaccination. Horses had rising levels of plaque-neutralizing and hemagglutinin-inhibiting antibodies shortly after injection with the 1st and 2nd doses of the vaccine (given 3 weeks apart) and were refractory to c...
Enzootic and epizootic Venezuelan equine encephalomyelitis virus in horses infected by peripheral and intrathecal routes. Forty-five horses were infected peripherally or intrathecally with enzootic or epizootic strains of Venezuelan equine encephalomyelitis (VEE) virus. Low titers of virus appeared in cerebrospinal fluid (CSF) after peripheral inoculation of enzootic or epizootic VEE virus strains. Intrathecal infection with either epizootic or enzootic VEE virus produced higher titers of virus in CSF than did peripheral infection. In contrast to peripheral infections with enzootic strains, intrathecal infections with these strains caused death. The animals that died had widespread histopathologic changes and lar...
Vaccination against diseases associated with herpesvirus infections in animals: a review. An account is presented of the development and use of herpesvirus vaccines in domestic animals, with particular reference to those viruses causing cytolytic rather than oncogenic infections. The chief infections covered are Aujeszky's disease (AD or pseudorabies), infectious bovine rhinotracheitis (IBR) and equine rhinopneumonitis (equine abortion; EHV-1). Others mentioned are feline viral rhinotracheitis and malignant catarrhal fever of cattle. Both live-modified and inactivated vaccines are widely used or under development for ADV, IBR and EHV-1. Live vaccines are generally regarded as succe...
A three-year evaluation of four commercial equine influenza vaccines in ponies maintained in isolation. Ponies held in isolation for 40 months were vaccinated and revaccinated with four commercial equine influenza vaccines. Little or no HI antibody was detected after the first inoculation; second and subsequent annual revaccinations produced peak HI antibody titres between 7 and 14 days. Titres fell quickly between 14 and 28 days and less quickly thereafter. The decline of HI antibody appeared to be related more to the initial titre attained and to the period after vaccination than to the composition of the vaccine. The response to a first annual revaccination was superior to that produced by a ...
[Outbreak of equine influenza by a new strain of Myxovirus type 2. II. Epizootiology]. During an epizootic of equine acute respiratory disease in Algeria, a strain of equine influenza virus was isolated. Sera examination by hemagglutinin inhibition test and complement fixation test confirmed the etiology of the disease. The first and second outbreak of the disease remained localised. The third outbreak spread within few months to all parts of the country. Horses vaccinated with a commercial equine influenza vaccine remained healthy.
Immunization of man and animals against influenza by oral and intranasal routes. Live human and equine influenza virus strains modified by serial passage on allantois-on-shell system (AOS) in the presence of normal horse serum were administered orally or intranasally to volunteers or horses. Mostly mild clinical short-lasting reactions, replication in nasal mucosae, transmission to placebo recipients and significant local or circulating antibody rises were observed following administration to volunteers of strains modified by five or less serial passages on AOS in the presence of normal horse serum (NHS). Milder clinical reactions, no replication, no viral transmission and...
Laboratory studies of Venezuelan equine encephalitis virus in equines, Texas, 1971. During the summer and fall of 1971, epizootic and epidemic Venezuelan equine encephalitis was detected in Texas. Isolates of epizootic (IB) and vaccine (TC-83) strains were distinguished by virulence of the former for guinea pigs. Vaccine virus was isolated from 1 to 14 days after vaccination and neutralization tests demonstrated the appearance of antibody about a week after vaccination. Viremia titers of subtype IB in horses ranged from 2.2 to 8.3 log10 suckling mouse intracranial 50% lethal doses per ml. Of 101 equines from which Venezuelan equine encephalitis virus (IB or TC-83) strains wer...
[Preparation and comparative evaluation of experimental anthrax diagnostic sera in experiments on animals]. The authors present the results of studies on obtaining and comparative assessment of experimental anthrax diagnostic sera in experiments on various animals. Donkeys, sheep, horses, rabbits and monkeys (Papio hamadryas) were immunized with the STI-I vaccine by a single scheme. The activity of the obtained sera was tested in the diffuse precipitation reaction by the amount of the detected antibodies and the titre. The most active sera were obtained from donkeys and sheep: their titre was 5.5 and 4 times greater and amount of the detected antibodies 2.6--2 times greater than in the sera of horse...
[Contribution to the antigenic study of influenza viruses in animals. II.–Antibodies, antineuraminidase in horse: conditions of apparition and importance (author’s transl)]. In the first part of this paper the conditions for a specific titration of antibodies against the neuraminidase (N) of each of the two horse virus subtypes are defined. The antigens used are: the H72Neq 1 recombining agent to measure the anti Neq1 antibodies and the A/Duck/Ukraine/63 strain for the anti Neq2 antibodies. The immunity response to neuraminidase appears after the natural disease; this response is studied in two foci, one due to a virus belonging to the A equi I subtype (Loire 73 strain), the other to a virus of the A equi 2 subtype (SHN 73 strain). The kinetics of apparition of an...
Purification and antigenicity of an M-like protein of Streptococcus equi. A cell wall component of Streptococcus equi analogous to the M protein of group A streptococci has been identified and purified. A highly purified product has been obtained from cells by hot acid extraction, followed by acid precipitation, ammonium sulfate fractionation, and column chromatography. This product reacts with S. equi antiserum. The existence of this fraction in S. equi has been confirmed by the failure of trypsin-treated cells and their extracts to remove the long-chaining capacity of S. equi antiserum. The antigenicity of this M-like protein when incorporated in adjuvant has been...
Comparison of SN and HI antibody dose response curves in chickens, rabbits, foals and horses following vaccination with equine influenza vaccine. After vaccination of chickens, rabbits, foals and horses, HI and SN antibody dose response curves were compared for A/Equi 1/Prague and A/Equi 2/Paris strains.
The two curves are parallel for a given strain and the relationship of HI and SN titres is constant, whatever the animal species.
The distribution of HI and SN titres varies for the two strains.
This variation, which is independent of animal species, may be related to the number of sites necessary for the antigenic-antibody response in vitro.
It is suggested that the testing of equine influenza vaccine be carried out in the ...